FGF-19 or FGF-21 analogs, dual antagonist of chemokine receptors 2 and 5 and antilysyloxidase-like-2 monoclonal antibodies are examples of the diversity of drugs that are being tested for the treatment of NASH.157. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatohepatitis.